

Jiang Cao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2175541/publications.pdf>

Version: 2024-02-01

42
papers

1,190
citations

331670

21
h-index

377865

34
g-index

46
all docs

46
docs citations

46
times ranked

2124
citing authors

#	ARTICLE	IF	CITATIONS
1	LncRNA UCA1 in anti-cancer drug resistance. <i>Oncotarget</i> , 2017, 8, 64638-64650.	1.8	119
2	Role of SIRT1 and AMPK in mesenchymal stem cells differentiation. <i>Ageing Research Reviews</i> , 2014, 13, 55-64.	10.9	89
3	Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 57, 751-758.	2.4	85
4	ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. <i>Anticancer Research</i> , 2008, 28, 479-83.	1.1	77
5	Estrogen receptors in gastric cancer: Advances and perspectives. <i>World Journal of Gastroenterology</i> , 2016, 22, 2475.	3.3	62
6	Estrogen receptor-36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. <i>Molecular Oncology</i> , 2013, 7, 611-624.	4.6	61
7	Simultaneous determination of quercetin, kaempferol and isorhamnetin accumulated human breast cancer cells, by high-performance liquid chromatography. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 39, 328-333.	2.8	55
8	Genetic characterization and disease mechanism of retinitis pigmentosa; current scenario. <i>3 Biotech</i> , 2017, 7, 251.	2.2	53
9	Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. <i>World Journal of Gastroenterology</i> , 2005, 11, 6202.	3.3	51
10	MicroRNAs in colorectal cancer as markers and targets: Recent advances. <i>World Journal of Gastroenterology</i> , 2014, 20, 4288.	3.3	45
11	Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer. <i>Oncotarget</i> , 2017, 8, 52156-52177.	1.8	40
12	Transcriptional analysis of estrogen receptor alpha variant mRNAs in colorectal cancers and their matched normal colorectal tissues. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008, 112, 20-24.	2.5	39
13	Estrogen-independent effects of ER-36 in ER-negative breast cancer. <i>Steroids</i> , 2012, 77, 666-673.	1.8	36
14	Translational regulator eIF2 in tumor. <i>Tumor Biology</i> , 2014, 35, 6255-6264.	1.8	30
15	The left dorsolateral prefrontal cortex volume is reduced in adults reporting childhood trauma independent of depression diagnosis. <i>Journal of Psychiatric Research</i> , 2019, 112, 12-17.	3.1	30
16	Stereoselective transport and uptake of propranolol across human intestinal Caco-2 cell monolayers. <i>Chirality</i> , 2010, 22, 361-368.	2.6	27
17	ER-36: a novel biomarker and potential therapeutic target in breast cancer. <i>OncoTargets and Therapy</i> , 2014, 7, 1525.	2.0	27
18	Involvement of Annexin A1 in Multidrug Resistance of K562/ADR Cells Identified by the Proteomic Study. <i>OMICS A Journal of Integrative Biology</i> , 2009, 13, 467-476.	2.0	26

#	ARTICLE	IF	CITATIONS
19	The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors. <i>Journal of Translational Medicine</i> , 2014, 12, 16.	4.4	25
20	Nuclear Localization of Annexin A1 Correlates With Advanced Disease and Peritoneal Dissemination in Patients with Gastric Carcinoma. <i>Anatomical Record</i> , 2010, 293, 1310-1314.	1.4	24
21	Advances in the targeted therapy of liposarcoma. <i>OncoTargets and Therapy</i> , 2015, 8, 125.	2.0	22
22	Quantitative profiles of the mRNAs of ER- $\hat{1}\pm$ and its novel variant ER- $\hat{1}\pm$ 36 in breast cancers and matched normal tissues. <i>Journal of Zhejiang University: Science B</i> , 2010, 11, 144-150.	2.8	18
23	Association between Mitogen-Activated Protein Kinase Kinase Kinase 1 Polymorphisms and Breast Cancer Susceptibility: A Meta-Analysis of 20 Case-Control Studies. <i>PLoS ONE</i> , 2014, 9, e90771.	2.5	14
24	Circulating Adiponectin and Risk of Endometrial Cancer. <i>PLoS ONE</i> , 2015, 10, e0129824.	2.5	13
25	Nuclear distribution of eIF3g and its interacting nuclear proteins in breast cancer cells. <i>Molecular Medicine Reports</i> , 2016, 13, 2973-2980.	2.4	12
26	FP3: a novel VEGF blocker with antiangiogenic effects in vitro and antitumour effects in vivo. <i>Clinical and Translational Oncology</i> , 2011, 13, 878-884.	2.4	11
27	Hepatocyte growth factor activator inhibitor type-1 in cancer: Advances and perspectives (Review). <i>Molecular Medicine Reports</i> , 2014, 10, 2779-2785.	2.4	11
28	Sensitization of gastric cancer cells to alkylating agents by glaucocalyxin B via cell cycle arrest and enhanced cell death. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2431-2441.	4.3	11
29	ER- $\hat{1}\pm$ 36 is an effective target of epigallocatechin-3-gallate in hepatocellular carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 3222-3234.	0.5	10
30	Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia. <i>Journal of Translational Medicine</i> , 2016, 14, 82.	4.4	9
31	Establishment and characterization of GCSR1, a multi-drug resistant signet ring cell gastric cancer cell line. <i>International Journal of Oncology</i> , 2015, 46, 2479-2487.	3.3	8
32	VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer. <i>Translational Oncology</i> , 2020, 13, 441-451.	3.7	8
33	Promoter Hypomethylation Is Responsible for Upregulated Expression of HAI-1 in Hepatocellular Carcinoma. <i>Disease Markers</i> , 2019, 2019, 1-12.	1.3	7
34	Effective inhibition of cancer cells by recombinant adenovirus expressing EGFR-targeting artificial microRNA and reversed-caspase-3. <i>PLoS ONE</i> , 2020, 15, e0237098.	2.5	7
35	Dendritic cells pulsed with GST-EGFR fusion protein: Effect in antitumor immunity against head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2010, 32, 626-635.	2.0	6
36	DNA Polymerases as targets for gene therapy of hepatocellular carcinoma. <i>BMC Cancer</i> , 2015, 15, 325.	2.6	6

#	ARTICLE	IF	CITATIONS
37	Down-regulation of HAI-1 is associated with poor-differentiation status of colorectal cancer. <i>Human Cell</i> , 2013, 26, 162-169.	2.7	4
38	CMV enhancer may not be suitable for tissue-specific enhancement of promoters in cancer gene therapy. <i>Cancer Gene Therapy</i> , 2020, 27, 389-392.	4.6	3
39	The construction and characterization of a novel adenovirus vector of artificial microRNA targeting EGFR. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 1968-1974.	0.5	3
40	Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line. <i>Pathology and Oncology Research</i> , 2017, 23, 829-835.	1.9	2
41	A novel multikinase inhibitor R8 exhibits potent inhibition on cancer cells through both apoptosis and autophagic cell death. <i>Oncotarget</i> , 2017, 8, 87209-87220.	1.8	1
42	Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target. <i>International Journal of Oncology</i> , 2020, 56, 761-771.	3.3	1